Dr. Xiaowen Ding 丁小文
Chief Physician
Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Screening, diagnosis, and treatment of early-stage breast cancer; diagnosis and treatment of familial hereditary breast cancer.
Dr. Ding holds a doctoral degree from Zhejiang University and has practiced since 2000. Research focuses on chemoprevention of malignant breast tumors, basic and clinical applications for benign and malignant breast tumors, early diagnosis, comprehensive surgical treatment, and functional preservation in breast cancer surgery. Dr. Ding has led two health department projects, published over ten articles, and co-edited one book on tumor health consultation.
Name order: in Chinese the family name comes first (Ding Xiaowen). Papers usually list the name as Xiaowen Ding or Ding X.
Selected publications
30 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Med Insights Oncol, 2023 (senior author): The Value of Neoadjuvant Anthracycline-Based Regimens for HER2-Positive Breast Cancer: A Systematic Review and Meta-analysis Including 1366 Patients. PubMed 37744425
- Oncol Res Treat, 2023 (senior author): Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. PubMed 37302393
- Front Cell Dev Biol, 2021 (senior author): Study of lncRNA TPA in Promoting Invasion and Metastasis of Breast Cancer Mediated by TGF-β Signaling Pathway. PubMed 34422811
- PLoS One, 2020 (senior author): Identification of a 6-gene signature for the survival prediction of breast cancer patients based on integrated multi-omics data analysis. PubMed 33170908
- PLoS One, 2020 (senior author): Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients. PubMed 32470093
- PLoS One, 2020 (senior author): Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer. PubMed 32298374
- Breast J, 2020 (senior author): Associations between folate metabolism enzyme polymorphisms and breast cancer: A meta-analysis. PubMed 31549463
- Oncol Lett, 2019 (senior author): Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China. PubMed 31807179
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion